The global market for Attention-Deficit Hyperactivity Disorder (ADHD) Medications was valued at US$ 13240 million in the year 2024 and is projected to reach a revised size of US$ 18650 million by 2031, growing at a CAGR of 4.9% during the forecast period.

Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market

Attention-Deficit Hyperactivity Disorder (ADHD) medications are prescription drugs used to treat individuals with ADHD by improving focus, reducing impulsive behaviors, and controlling hyperactivity. Common types include central nervous system stimulants such as methylphenidate (Ritalin) and amphetamine-based drugs (Adderall), as well as non-stimulant options like atomoxetine (Strattera). These medications work by altering levels of key neurotransmitters—mainly dopamine and norepinephrine—in the brain to enhance cognitive function and behavioral regulation. ADHD medications are widely prescribed for children, adolescents, and adults as part of a long-term treatment strategy.

The global ADHD medications market is primarily driven by the rising prevalence of ADHD diagnoses across both pediatric and adult populations. Increased awareness and acceptance of mental health disorders, particularly in developed countries, have led to early screening and higher diagnosis rates. Additionally, growing educational pressures and the expansion of behavioral health services have encouraged more individuals to seek medical treatment. Technological advancements in digital health have also facilitated telepsychiatry and online prescription platforms, making ADHD medications more accessible. Moreover, the pharmaceutical industry has invested heavily in developing extended-release and non-stimulant formulations to improve efficacy and reduce side effects, which has expanded treatment options. In emerging markets, improving healthcare infrastructure and the reduction of stigma surrounding mental disorders are further contributing to the growing demand for ADHD medications.

Despite strong demand, the ADHD medications market faces significant challenges. One major concern is the potential for misuse and dependency, particularly with stimulant-based drugs like amphetamines, which are classified as controlled substances. This has led to stringent regulatory oversight and prescribing restrictions, especially in the U.S. and Europe. Additionally, many ADHD medications are associated with side effects such as insomnia, appetite loss, mood swings, and cardiovascular issues, which can affect treatment adherence and patient outcomes. The high cost of brand-name medications and the inconsistent availability of generics in some regions can also limit access. Another challenge is the underdiagnosis or misdiagnosis of ADHD in certain populations, including females and adults, due to gender bias or lack of specialized care. These issues collectively create hurdles for market expansion and patient management.

This report aims to provide a comprehensive presentation of the global market for Attention-Deficit Hyperactivity Disorder (ADHD) Medications, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Attention-Deficit Hyperactivity Disorder (ADHD) Medications.

The Attention-Deficit Hyperactivity Disorder (ADHD) Medications market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Attention-Deficit Hyperactivity Disorder (ADHD) Medications market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Attention-Deficit Hyperactivity Disorder (ADHD) Medications companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Market Segmentation

Scope of Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market Report

Report Metric	Details
Report Name	Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market
Accounted market size in year	US$ 13240 million
Forecasted market size in 2031	US$ 18650 million
CAGR	4.9%
Base Year	year
Forecasted years	2025 - 2031
Segment by Type	Stimulants Non-stimulants
Segment by Application	Hospital Clinic Others
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	Takeda, Johnson & Johnson, Novartis, Eli Lilly, Tris Pharma, Neos Therapeutics, Mallinckrodt, Amneal Pharmaceuticals, Noven Pharmaceuticals, Purdue Parma, Zhengdafenhai, Highland Therapeutics, Jubilant Life Sciences, Medice Arzneimittel Putter, Lannett
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Attention-Deficit Hyperactivity Disorder (ADHD) Medications company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

FAQ for this report

How fast is Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market growing?

Ans: The Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market witnessing a CAGR of 4.9% during the forecast period 2025-2031.

What is the Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market size in 2031?

Ans: The Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market size in 2031 will be US$ 18650 million.

Who are the main players in the Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market report?

Ans: The main players in the Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market are Takeda, Johnson & Johnson, Novartis, Eli Lilly, Tris Pharma, Neos Therapeutics, Mallinckrodt, Amneal Pharmaceuticals, Noven Pharmaceuticals, Purdue Parma, Zhengdafenhai, Highland Therapeutics, Jubilant Life Sciences, Medice Arzneimittel Putter, Lannett

What are the Application segmentation covered in the Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market report?

Ans: The Applications covered in the Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market report are Hospital, Clinic, Others

What are the Type segmentation covered in the Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market report?

Ans: The Types covered in the Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market report are Stimulants, Non-stimulants

1 Report Overview

1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market Size Growth Rate by Type: 2020 VS 2024 VS 2031

1.2.2 Stimulants

1.2.3 Non-stimulants

1.3 Market by Application

1.3.1 Global Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market Growth by Application: 2020 VS 2024 VS 2031

1.3.2 Hospital

1.3.3 Clinic

1.3.4 Others

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Global Growth Trends

2.1 Global Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market Perspective (2020-2031)

2.2 Global Attention-Deficit Hyperactivity Disorder (ADHD) Medications Growth Trends by Region

2.2.1 Global Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market Size by Region: 2020 VS 2024 VS 2031

2.2.2 Attention-Deficit Hyperactivity Disorder (ADHD) Medications Historic Market Size by Region (2020-2025)

2.2.3 Attention-Deficit Hyperactivity Disorder (ADHD) Medications Forecasted Market Size by Region (2026-2031)

2.3 Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market Dynamics

2.3.1 Attention-Deficit Hyperactivity Disorder (ADHD) Medications Industry Trends

2.3.2 Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market Drivers

2.3.3 Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market Challenges

2.3.4 Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market Restraints

3 Competition Landscape by Key Players

3.1 Global Top Attention-Deficit Hyperactivity Disorder (ADHD) Medications Players by Revenue

3.1.1 Global Top Attention-Deficit Hyperactivity Disorder (ADHD) Medications Players by Revenue (2020-2025)

3.1.2 Global Attention-Deficit Hyperactivity Disorder (ADHD) Medications Revenue Market Share by Players (2020-2025)

3.2 Global Top Attention-Deficit Hyperactivity Disorder (ADHD) Medications Players by Company Type and Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.3 Global Key Players Ranking by Attention-Deficit Hyperactivity Disorder (ADHD) Medications Revenue

3.4 Global Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market Concentration Ratio

3.4.1 Global Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by Attention-Deficit Hyperactivity Disorder (ADHD) Medications Revenue in 2024

3.5 Global Key Players of Attention-Deficit Hyperactivity Disorder (ADHD) Medications Head office and Area Served

3.6 Global Key Players of Attention-Deficit Hyperactivity Disorder (ADHD) Medications, Product and Application

3.7 Global Key Players of Attention-Deficit Hyperactivity Disorder (ADHD) Medications, Date of Enter into This Industry

3.8 Mergers & Acquisitions, Expansion Plans

4 Attention-Deficit Hyperactivity Disorder (ADHD) Medications Breakdown Data by Type

4.1 Global Attention-Deficit Hyperactivity Disorder (ADHD) Medications Historic Market Size by Type (2020-2025)

4.2 Global Attention-Deficit Hyperactivity Disorder (ADHD) Medications Forecasted Market Size by Type (2026-2031)

5 Attention-Deficit Hyperactivity Disorder (ADHD) Medications Breakdown Data by Application

5.1 Global Attention-Deficit Hyperactivity Disorder (ADHD) Medications Historic Market Size by Application (2020-2025)

5.2 Global Attention-Deficit Hyperactivity Disorder (ADHD) Medications Forecasted Market Size by Application (2026-2031)

6 North America

6.1 North America Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market Size (2020-2031)

6.2 North America Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market Growth Rate by Country: 2020 VS 2024 VS 2031

6.3 North America Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market Size by Country (2020-2025)

6.4 North America Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market Size by Country (2026-2031)

6.5 United States

6.6 Canada

7 Europe

7.1 Europe Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market Size (2020-2031)

7.2 Europe Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market Growth Rate by Country: 2020 VS 2024 VS 2031

7.3 Europe Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market Size by Country (2020-2025)

7.4 Europe Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market Size by Country (2026-2031)

7.5 Germany

7.6 France

7.7 U.K.

7.8 Italy

7.9 Russia

7.10 Nordic Countries

8 Asia-Pacific

8.1 Asia-Pacific Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market Size (2020-2031)

8.2 Asia-Pacific Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market Growth Rate by Region: 2020 VS 2024 VS 2031

8.3 Asia-Pacific Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market Size by Region (2020-2025)

8.4 Asia-Pacific Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market Size by Region (2026-2031)

8.5 China

8.6 Japan

8.7 South Korea

8.8 Southeast Asia

8.9 India

8.10 Australia

9 Latin America

9.1 Latin America Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market Size (2020-2031)

9.2 Latin America Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market Growth Rate by Country: 2020 VS 2024 VS 2031

9.3 Latin America Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market Size by Country (2020-2025)

9.4 Latin America Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market Size by Country (2026-2031)

9.5 Mexico

9.6 Brazil

10 Middle East & Africa

10.1 Middle East & Africa Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market Size (2020-2031)

10.2 Middle East & Africa Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market Growth Rate by Country: 2020 VS 2024 VS 2031

10.3 Middle East & Africa Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market Size by Country (2020-2025)

10.4 Middle East & Africa Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market Size by Country (2026-2031)

10.5 Turkey

10.6 Saudi Arabia

10.7 UAE

11 Key Players Profiles

11.1 Takeda

11.1.1 Takeda Company Details

11.1.2 Takeda Business Overview

11.1.3 Takeda Attention-Deficit Hyperactivity Disorder (ADHD) Medications Introduction

11.1.4 Takeda Revenue in Attention-Deficit Hyperactivity Disorder (ADHD) Medications Business (2020-2025)

11.1.5 Takeda Recent Development

11.2 Johnson & Johnson

11.2.1 Johnson & Johnson Company Details

11.2.2 Johnson & Johnson Business Overview

11.2.3 Johnson & Johnson Attention-Deficit Hyperactivity Disorder (ADHD) Medications Introduction

11.2.4 Johnson & Johnson Revenue in Attention-Deficit Hyperactivity Disorder (ADHD) Medications Business (2020-2025)

11.2.5 Johnson & Johnson Recent Development

11.3 Novartis

11.3.1 Novartis Company Details

11.3.2 Novartis Business Overview

11.3.3 Novartis Attention-Deficit Hyperactivity Disorder (ADHD) Medications Introduction

11.3.4 Novartis Revenue in Attention-Deficit Hyperactivity Disorder (ADHD) Medications Business (2020-2025)

11.3.5 Novartis Recent Development

11.4 Eli Lilly

11.4.1 Eli Lilly Company Details

11.4.2 Eli Lilly Business Overview

11.4.3 Eli Lilly Attention-Deficit Hyperactivity Disorder (ADHD) Medications Introduction

11.4.4 Eli Lilly Revenue in Attention-Deficit Hyperactivity Disorder (ADHD) Medications Business (2020-2025)

11.4.5 Eli Lilly Recent Development

11.5 Tris Pharma

11.5.1 Tris Pharma Company Details

11.5.2 Tris Pharma Business Overview

11.5.3 Tris Pharma Attention-Deficit Hyperactivity Disorder (ADHD) Medications Introduction

11.5.4 Tris Pharma Revenue in Attention-Deficit Hyperactivity Disorder (ADHD) Medications Business (2020-2025)

11.5.5 Tris Pharma Recent Development

11.6 Neos Therapeutics

11.6.1 Neos Therapeutics Company Details

11.6.2 Neos Therapeutics Business Overview

11.6.3 Neos Therapeutics Attention-Deficit Hyperactivity Disorder (ADHD) Medications Introduction

11.6.4 Neos Therapeutics Revenue in Attention-Deficit Hyperactivity Disorder (ADHD) Medications Business (2020-2025)

11.6.5 Neos Therapeutics Recent Development

11.7 Mallinckrodt

11.7.1 Mallinckrodt Company Details

11.7.2 Mallinckrodt Business Overview

11.7.3 Mallinckrodt Attention-Deficit Hyperactivity Disorder (ADHD) Medications Introduction

11.7.4 Mallinckrodt Revenue in Attention-Deficit Hyperactivity Disorder (ADHD) Medications Business (2020-2025)

11.7.5 Mallinckrodt Recent Development

11.8 Amneal Pharmaceuticals

11.8.1 Amneal Pharmaceuticals Company Details

11.8.2 Amneal Pharmaceuticals Business Overview

11.8.3 Amneal Pharmaceuticals Attention-Deficit Hyperactivity Disorder (ADHD) Medications Introduction

11.8.4 Amneal Pharmaceuticals Revenue in Attention-Deficit Hyperactivity Disorder (ADHD) Medications Business (2020-2025)

11.8.5 Amneal Pharmaceuticals Recent Development

11.9 Noven Pharmaceuticals

11.9.1 Noven Pharmaceuticals Company Details

11.9.2 Noven Pharmaceuticals Business Overview

11.9.3 Noven Pharmaceuticals Attention-Deficit Hyperactivity Disorder (ADHD) Medications Introduction

11.9.4 Noven Pharmaceuticals Revenue in Attention-Deficit Hyperactivity Disorder (ADHD) Medications Business (2020-2025)

11.9.5 Noven Pharmaceuticals Recent Development

11.10 Purdue Parma

11.10.1 Purdue Parma Company Details

11.10.2 Purdue Parma Business Overview

11.10.3 Purdue Parma Attention-Deficit Hyperactivity Disorder (ADHD) Medications Introduction

11.10.4 Purdue Parma Revenue in Attention-Deficit Hyperactivity Disorder (ADHD) Medications Business (2020-2025)

11.10.5 Purdue Parma Recent Development

11.11 Zhengdafenhai

11.11.1 Zhengdafenhai Company Details

11.11.2 Zhengdafenhai Business Overview

11.11.3 Zhengdafenhai Attention-Deficit Hyperactivity Disorder (ADHD) Medications Introduction

11.11.4 Zhengdafenhai Revenue in Attention-Deficit Hyperactivity Disorder (ADHD) Medications Business (2020-2025)

11.11.5 Zhengdafenhai Recent Development

11.12 Highland Therapeutics

11.12.1 Highland Therapeutics Company Details

11.12.2 Highland Therapeutics Business Overview

11.12.3 Highland Therapeutics Attention-Deficit Hyperactivity Disorder (ADHD) Medications Introduction

11.12.4 Highland Therapeutics Revenue in Attention-Deficit Hyperactivity Disorder (ADHD) Medications Business (2020-2025)

11.12.5 Highland Therapeutics Recent Development

11.13 Jubilant Life Sciences

11.13.1 Jubilant Life Sciences Company Details

11.13.2 Jubilant Life Sciences Business Overview

11.13.3 Jubilant Life Sciences Attention-Deficit Hyperactivity Disorder (ADHD) Medications Introduction

11.13.4 Jubilant Life Sciences Revenue in Attention-Deficit Hyperactivity Disorder (ADHD) Medications Business (2020-2025)

11.13.5 Jubilant Life Sciences Recent Development

11.14 Medice Arzneimittel Putter

11.14.1 Medice Arzneimittel Putter Company Details

11.14.2 Medice Arzneimittel Putter Business Overview

11.14.3 Medice Arzneimittel Putter Attention-Deficit Hyperactivity Disorder (ADHD) Medications Introduction

11.14.4 Medice Arzneimittel Putter Revenue in Attention-Deficit Hyperactivity Disorder (ADHD) Medications Business (2020-2025)

11.14.5 Medice Arzneimittel Putter Recent Development

11.15 Lannett

11.15.1 Lannett Company Details

11.15.2 Lannett Business Overview

11.15.3 Lannett Attention-Deficit Hyperactivity Disorder (ADHD) Medications Introduction

11.15.4 Lannett Revenue in Attention-Deficit Hyperactivity Disorder (ADHD) Medications Business (2020-2025)

11.15.5 Lannett Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.1.1 Research Programs/Design

13.1.1.2 Market Size Estimation

13.1.1.3 Market Breakdown and Data Triangulation

13.1.2 Data Source

13.1.2.1 Secondary Sources

13.1.2.2 Primary Sources

13.2 Author Details

13.3 Disclaimer

FEATURED COMPANIES

Amneal Pharmaceuticals

Noven Pharmaceuticals

Purdue Parma

Jubilant Life Sciences

Lannett

Zhengdafenhai

Highland Therapeutics

Medice Arzneimittel Putter

List of Tables

Table 1. Global Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031

Table 2. Key Players of Stimulants

Table 3. Key Players of Non-stimulants

Table 4. Global Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031

Table 5. Global Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market Size by Region (US$ Million): 2020 VS 2024 VS 2031

Table 6. Global Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market Size by Region (2020-2025) & (US$ Million)

Table 7. Global Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market Share by Region (2020-2025)

Table 8. Global Attention-Deficit Hyperactivity Disorder (ADHD) Medications Forecasted Market Size by Region (2026-2031) & (US$ Million)

Table 9. Global Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market Share by Region (2026-2031)

Table 10. Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market Trends

Table 11. Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market Drivers

Table 12. Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market Challenges

Table 13. Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market Restraints

Table 14. Global Attention-Deficit Hyperactivity Disorder (ADHD) Medications Revenue by Players (2020-2025) & (US$ Million)

Table 15. Global Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market Share by Players (2020-2025)

Table 16. Global Top Attention-Deficit Hyperactivity Disorder (ADHD) Medications Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Attention-Deficit Hyperactivity Disorder (ADHD) Medications as of 2024)

Table 17. Ranking of Global Top Attention-Deficit Hyperactivity Disorder (ADHD) Medications Companies by Revenue (US$ Million) in 2024

Table 18. Global 5 Largest Players Market Share by Attention-Deficit Hyperactivity Disorder (ADHD) Medications Revenue (CR5 and HHI) & (2020-2025)

Table 19. Global Key Players of Attention-Deficit Hyperactivity Disorder (ADHD) Medications, Headquarters and Area Served

Table 20. Global Key Players of Attention-Deficit Hyperactivity Disorder (ADHD) Medications, Product and Application

Table 21. Global Key Players of Attention-Deficit Hyperactivity Disorder (ADHD) Medications, Date of Enter into This Industry

Table 22. Mergers & Acquisitions, Expansion Plans

Table 23. Global Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market Size by Type (2020-2025) & (US$ Million)

Table 24. Global Attention-Deficit Hyperactivity Disorder (ADHD) Medications Revenue Market Share by Type (2020-2025)

Table 25. Global Attention-Deficit Hyperactivity Disorder (ADHD) Medications Forecasted Market Size by Type (2026-2031) & (US$ Million)

Table 26. Global Attention-Deficit Hyperactivity Disorder (ADHD) Medications Revenue Market Share by Type (2026-2031)

Table 27. Global Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market Size by Application (2020-2025) & (US$ Million)

Table 28. Global Attention-Deficit Hyperactivity Disorder (ADHD) Medications Revenue Market Share by Application (2020-2025)

Table 29. Global Attention-Deficit Hyperactivity Disorder (ADHD) Medications Forecasted Market Size by Application (2026-2031) & (US$ Million)

Table 30. Global Attention-Deficit Hyperactivity Disorder (ADHD) Medications Revenue Market Share by Application (2026-2031)

Table 31. North America Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 32. North America Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market Size by Country (2020-2025) & (US$ Million)

Table 33. North America Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market Size by Country (2026-2031) & (US$ Million)

Table 34. Europe Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 35. Europe Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market Size by Country (2020-2025) & (US$ Million)

Table 36. Europe Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market Size by Country (2026-2031) & (US$ Million)

Table 37. Asia-Pacific Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031

Table 38. Asia-Pacific Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market Size by Region (2020-2025) & (US$ Million)

Table 39. Asia-Pacific Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market Size by Region (2026-2031) & (US$ Million)

Table 40. Latin America Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 41. Latin America Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market Size by Country (2020-2025) & (US$ Million)

Table 42. Latin America Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market Size by Country (2026-2031) & (US$ Million)

Table 43. Middle East & Africa Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 44. Middle East & Africa Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market Size by Country (2020-2025) & (US$ Million)

Table 45. Middle East & Africa Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market Size by Country (2026-2031) & (US$ Million)

Table 46. Takeda Company Details

Table 47. Takeda Business Overview

Table 48. Takeda Attention-Deficit Hyperactivity Disorder (ADHD) Medications Product

Table 49. Takeda Revenue in Attention-Deficit Hyperactivity Disorder (ADHD) Medications Business (2020-2025) & (US$ Million)

Table 50. Takeda Recent Development

Table 51. Johnson & Johnson Company Details

Table 52. Johnson & Johnson Business Overview

Table 53. Johnson & Johnson Attention-Deficit Hyperactivity Disorder (ADHD) Medications Product

Table 54. Johnson & Johnson Revenue in Attention-Deficit Hyperactivity Disorder (ADHD) Medications Business (2020-2025) & (US$ Million)

Table 55. Johnson & Johnson Recent Development

Table 56. Novartis Company Details

Table 57. Novartis Business Overview

Table 58. Novartis Attention-Deficit Hyperactivity Disorder (ADHD) Medications Product

Table 59. Novartis Revenue in Attention-Deficit Hyperactivity Disorder (ADHD) Medications Business (2020-2025) & (US$ Million)

Table 60. Novartis Recent Development

Table 61. Eli Lilly Company Details

Table 62. Eli Lilly Business Overview

Table 63. Eli Lilly Attention-Deficit Hyperactivity Disorder (ADHD) Medications Product

Table 64. Eli Lilly Revenue in Attention-Deficit Hyperactivity Disorder (ADHD) Medications Business (2020-2025) & (US$ Million)

Table 65. Eli Lilly Recent Development

Table 66. Tris Pharma Company Details

Table 67. Tris Pharma Business Overview

Table 68. Tris Pharma Attention-Deficit Hyperactivity Disorder (ADHD) Medications Product

Table 69. Tris Pharma Revenue in Attention-Deficit Hyperactivity Disorder (ADHD) Medications Business (2020-2025) & (US$ Million)

Table 70. Tris Pharma Recent Development

Table 71. Neos Therapeutics Company Details

Table 72. Neos Therapeutics Business Overview

Table 73. Neos Therapeutics Attention-Deficit Hyperactivity Disorder (ADHD) Medications Product

Table 74. Neos Therapeutics Revenue in Attention-Deficit Hyperactivity Disorder (ADHD) Medications Business (2020-2025) & (US$ Million)

Table 75. Neos Therapeutics Recent Development

Table 76. Mallinckrodt Company Details

Table 77. Mallinckrodt Business Overview

Table 78. Mallinckrodt Attention-Deficit Hyperactivity Disorder (ADHD) Medications Product

Table 79. Mallinckrodt Revenue in Attention-Deficit Hyperactivity Disorder (ADHD) Medications Business (2020-2025) & (US$ Million)

Table 80. Mallinckrodt Recent Development

Table 81. Amneal Pharmaceuticals Company Details

Table 82. Amneal Pharmaceuticals Business Overview

Table 83. Amneal Pharmaceuticals Attention-Deficit Hyperactivity Disorder (ADHD) Medications Product

Table 84. Amneal Pharmaceuticals Revenue in Attention-Deficit Hyperactivity Disorder (ADHD) Medications Business (2020-2025) & (US$ Million)

Table 85. Amneal Pharmaceuticals Recent Development

Table 86. Noven Pharmaceuticals Company Details

Table 87. Noven Pharmaceuticals Business Overview

Table 88. Noven Pharmaceuticals Attention-Deficit Hyperactivity Disorder (ADHD) Medications Product

Table 89. Noven Pharmaceuticals Revenue in Attention-Deficit Hyperactivity Disorder (ADHD) Medications Business (2020-2025) & (US$ Million)

Table 90. Noven Pharmaceuticals Recent Development

Table 91. Purdue Parma Company Details

Table 92. Purdue Parma Business Overview

Table 93. Purdue Parma Attention-Deficit Hyperactivity Disorder (ADHD) Medications Product

Table 94. Purdue Parma Revenue in Attention-Deficit Hyperactivity Disorder (ADHD) Medications Business (2020-2025) & (US$ Million)

Table 95. Purdue Parma Recent Development

Table 96. Zhengdafenhai Company Details

Table 97. Zhengdafenhai Business Overview

Table 98. Zhengdafenhai Attention-Deficit Hyperactivity Disorder (ADHD) Medications Product

Table 99. Zhengdafenhai Revenue in Attention-Deficit Hyperactivity Disorder (ADHD) Medications Business (2020-2025) & (US$ Million)

Table 100. Zhengdafenhai Recent Development

Table 101. Highland Therapeutics Company Details

Table 102. Highland Therapeutics Business Overview

Table 103. Highland Therapeutics Attention-Deficit Hyperactivity Disorder (ADHD) Medications Product

Table 104. Highland Therapeutics Revenue in Attention-Deficit Hyperactivity Disorder (ADHD) Medications Business (2020-2025) & (US$ Million)

Table 105. Highland Therapeutics Recent Development

Table 106. Jubilant Life Sciences Company Details

Table 107. Jubilant Life Sciences Business Overview

Table 108. Jubilant Life Sciences Attention-Deficit Hyperactivity Disorder (ADHD) Medications Product

Table 109. Jubilant Life Sciences Revenue in Attention-Deficit Hyperactivity Disorder (ADHD) Medications Business (2020-2025) & (US$ Million)

Table 110. Jubilant Life Sciences Recent Development

Table 111. Medice Arzneimittel Putter Company Details

Table 112. Medice Arzneimittel Putter Business Overview

Table 113. Medice Arzneimittel Putter Attention-Deficit Hyperactivity Disorder (ADHD) Medications Product

Table 114. Medice Arzneimittel Putter Revenue in Attention-Deficit Hyperactivity Disorder (ADHD) Medications Business (2020-2025) & (US$ Million)

Table 115. Medice Arzneimittel Putter Recent Development

Table 116. Lannett Company Details

Table 117. Lannett Business Overview

Table 118. Lannett Attention-Deficit Hyperactivity Disorder (ADHD) Medications Product

Table 119. Lannett Revenue in Attention-Deficit Hyperactivity Disorder (ADHD) Medications Business (2020-2025) & (US$ Million)

Table 120. Lannett Recent Development

Table 121. Research Programs/Design for This Report

Table 122. Key Data Information from Secondary Sources

Table 123. Key Data Information from Primary Sources

Table 124. Authors List of This Report

List of Figures

Figure 1. Attention-Deficit Hyperactivity Disorder (ADHD) Medications Picture

Figure 2. Global Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market Size Comparison by Type (2020-2031) & (US$ Million)

Figure 3. Global Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market Share by Type: 2024 VS 2031

Figure 4. Stimulants Features

Figure 5. Non-stimulants Features

Figure 6. Global Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market Size by Application (2020-2031) & (US$ Million)

Figure 7. Global Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market Share by Application: 2024 VS 2031

Figure 8. Hospital Case Studies

Figure 9. Clinic Case Studies

Figure 10. Others Case Studies

Figure 11. Attention-Deficit Hyperactivity Disorder (ADHD) Medications Report Years Considered

Figure 12. Global Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market Size (US$ Million), Year-over-Year: 2020-2031

Figure 13. Global Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market Size, (US$ Million), 2020 VS 2024 VS 2031

Figure 14. Global Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market Share by Region: 2024 VS 2031

Figure 15. Global Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market Share by Players in 2024

Figure 16. Global Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

Figure 17. The Top 10 and 5 Players Market Share by Attention-Deficit Hyperactivity Disorder (ADHD) Medications Revenue in 2024

Figure 18. North America Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 19. North America Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market Share by Country (2020-2031)

Figure 20. United States Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 21. Canada Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 22. Europe Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 23. Europe Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market Share by Country (2020-2031)

Figure 24. Germany Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 25. France Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 26. U.K. Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 27. Italy Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 28. Russia Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 29. Nordic Countries Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 30. Asia-Pacific Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 31. Asia-Pacific Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market Share by Region (2020-2031)

Figure 32. China Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 33. Japan Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 34. South Korea Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 35. Southeast Asia Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 36. India Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 37. Australia Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 38. Latin America Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 39. Latin America Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market Share by Country (2020-2031)

Figure 40. Mexico Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 41. Brazil Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 42. Middle East & Africa Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 43. Middle East & Africa Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market Share by Country (2020-2031)

Figure 44. Turkey Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 45. Saudi Arabia Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 46. UAE Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 47. Takeda Revenue Growth Rate in Attention-Deficit Hyperactivity Disorder (ADHD) Medications Business (2020-2025)

Figure 48. Johnson & Johnson Revenue Growth Rate in Attention-Deficit Hyperactivity Disorder (ADHD) Medications Business (2020-2025)

Figure 49. Novartis Revenue Growth Rate in Attention-Deficit Hyperactivity Disorder (ADHD) Medications Business (2020-2025)

Figure 50. Eli Lilly Revenue Growth Rate in Attention-Deficit Hyperactivity Disorder (ADHD) Medications Business (2020-2025)

Figure 51. Tris Pharma Revenue Growth Rate in Attention-Deficit Hyperactivity Disorder (ADHD) Medications Business (2020-2025)

Figure 52. Neos Therapeutics Revenue Growth Rate in Attention-Deficit Hyperactivity Disorder (ADHD) Medications Business (2020-2025)

Figure 53. Mallinckrodt Revenue Growth Rate in Attention-Deficit Hyperactivity Disorder (ADHD) Medications Business (2020-2025)

Figure 54. Amneal Pharmaceuticals Revenue Growth Rate in Attention-Deficit Hyperactivity Disorder (ADHD) Medications Business (2020-2025)

Figure 55. Noven Pharmaceuticals Revenue Growth Rate in Attention-Deficit Hyperactivity Disorder (ADHD) Medications Business (2020-2025)

Figure 56. Purdue Parma Revenue Growth Rate in Attention-Deficit Hyperactivity Disorder (ADHD) Medications Business (2020-2025)

Figure 57. Zhengdafenhai Revenue Growth Rate in Attention-Deficit Hyperactivity Disorder (ADHD) Medications Business (2020-2025)

Figure 58. Highland Therapeutics Revenue Growth Rate in Attention-Deficit Hyperactivity Disorder (ADHD) Medications Business (2020-2025)

Figure 59. Jubilant Life Sciences Revenue Growth Rate in Attention-Deficit Hyperactivity Disorder (ADHD) Medications Business (2020-2025)

Figure 60. Medice Arzneimittel Putter Revenue Growth Rate in Attention-Deficit Hyperactivity Disorder (ADHD) Medications Business (2020-2025)

Figure 61. Lannett Revenue Growth Rate in Attention-Deficit Hyperactivity Disorder (ADHD) Medications Business (2020-2025)

Figure 62. Bottom-up and Top-down Approaches for This Report

Figure 63. Data Triangulation

Figure 64. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$2900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Global Attention Deficit Hyperactivity Disorder Treatment Market Research Report 2024

Global Pediatric ADHD Drugs Market Research Report 2025

Global ADHD Medications Market Insights Forecast to 2030

Attention Deficit Hyperactivity Disorder ADHD Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

ADHD Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global ADHD Test Online Market Research Report 2025

Global Attention deficit Hyperactivity Disorder ADHD Therapeutics Market Research Report 2024

ADHD Therapeutics Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Methylphenidate Drug Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Attention Deficit Hyperactivity Disorder Therapeutics Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Attention Deficit Hyperactivity Disorder ADHD Market Size Manufacturers Supply Chain Sales Channel and Clients 2024 2030

Global Attention Deficit and Hyperactivity Disorder Market Research Report 2025

Global Children Attention Deficit and Hyperactivity Disorder Market Research Report 2025

Global ADHD Apps Market Research Report 2024

Global Adult Attention Deficit and Hyperactivity Disorder Market Research Report 2025

Global ADHD Drug Treatment Market Research Report 2024

Global Attention Deficit Hyperactivity Syndrome Treatment Market Research Report 2025

Psychiatric Medications Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Psychiatric Medication Therapies Market Research Report 2024

120 Pages

Type: Report

Code: QYRE-Auto-18B19448

Mon Jun 09 00:00:00 UTC 2025

Add to Cart

Global Spinal Cord Stimulation Devices Market Size, Manufacturers, Supply Chain, Sales Channel and Clients, 2025-2031

120 Pages

Type: Report

Code: QYRE-Auto-11Z11048

Mon Jun 09 00:00:00 UTC 2025

Add to Cart

Global Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-26G17123

Wed Jun 04 00:00:00 UTC 2025

Add to Cart

Global Hydrocephalus Shunts Market Size, Manufacturers, Supply Chain, Sales Channel and Clients, 2025-2031

120 Pages

Type: Report

Code: QYRE-Auto-9139

Wed Jun 04 00:00:00 UTC 2025

Add to Cart

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions

Global Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market Research Report 2025

Published Date: June 2025

Report Code: QYRE-Auto-26G17123

Global Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market Research Report 2025

FEATURED COMPANIES

Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market Size

Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market

Scope of Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market Report

Chapter Outline

FAQ for this report

How fast is Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market growing?

What is the Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market size in 2031?

Who are the main players in the Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market report?

What are the Application segmentation covered in the Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market report?

What are the Type segmentation covered in the Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market report?

FEATURED COMPANIES

RELATED REPORTS